Last data update: May 20, 2024. (Total: 46824 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Boswell HC[original query] |
---|
A Review of Adverse Events from the Use of Diphtheria Antitoxin (DAT) in the United States, 2004-2019
Bampoe VD , Boswell HC , Yu YC , Acosta AM . Clin Infect Dis 2021 74 (11) 2082-2083 We read with interest the analysis by Eisenberg and colleagues [1] on diphtheria antitoxin (DAT) use during the diphtheria outbreak in Bangladesh, especially with regard to product safety. Eisenberg et al found that administration of a DAT product manufactured by Premium Serum and Vaccines Pvt Ltd (India) was associated with adverse events (AEs) in 170 of 790 (24%) recipients. However, most events were mild, and anaphylaxis occurred in only 3% [1]. Here we provide further evidence on the safety of DAT, administered in a high-resource, non-outbreak setting in the United States. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 20, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure